Comments
Loading...
Canntab Therapeutics Analyst Ratings and Price Targets | OTC:CTABF | Benzinga
Canntab Therapeutics Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Canntab Therapeutics Corp from these most-recent analyst ratings.
Analyst Ratings for Canntab Therapeutics
| Buy Now | Get Alert | ||||||||
|---|---|---|---|---|---|---|---|---|---|
No data available to display | |||||||||
FAQ
What is the target price for Canntab Therapeutics (CTABF) stock?
There is no price target for Canntab Therapeutics
What is the most recent analyst rating for Canntab Therapeutics (CTABF)?
There is no analyst for Canntab Therapeutics
When was the last upgrade for Canntab Therapeutics (CTABF)?
There is no last upgrade for Canntab Therapeutics
When was the last downgrade for Canntab Therapeutics (CTABF)?
There is no last downgrade for Canntab Therapeutics.
When is the next analyst rating going to be posted or updated for Canntab Therapeutics (CTABF)?
There is no next analyst rating for Canntab Therapeutics.
Is the Analyst Rating Canntab Therapeutics (CTABF) correct?
There is no next analyst rating for Canntab Therapeutics.
Browse analyst ratings and price targets on all stocks.